Teva Pharmaceutical (TEVA) stock witnessed a significant pre-market plunge of 7.80% on Wednesday, following the company's disappointing Q4 earnings report and weak 2025 guidance.
The drug maker reported Q4 non-GAAP earnings of $0.71 per diluted share, lower than the $1.00 reported in the same quarter last year. While the earnings met analysts' expectations, the company's net revenue for the quarter declined to $4.23 billion from $4.46 billion a year earlier, missing the analysts' forecast of $4.15 billion.
Furthermore, Teva's 2025 outlook dampened investor sentiment. The company expects non-GAAP diluted EPS of $2.35 to $2.65 on revenue of $16.8 billion to $17.4 billion, falling short of analysts' estimates of non-GAAP EPS of $2.96 on revenue of $17.09 billion.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。